Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 13  Issue 2
Advances in cannabidiol research as an antipsychotic
Anand Gururajan, Daniel T. Malone, David A. Taylor
Pages: 17 - 23
Number of pages: 7
Current Topics in Pharmacology
Volume 13  Issue 2

Copyright © 2009 Research Trends. All rights reserved

Schizophrenia is a debilitating neurodegenerative disorder which affects 1% of the global population and is caused by a complex interaction between the genotype and the environment making it difficult to identify the multitude of genes and the external causatives which may predispose an individual towards developing schizophrenia.  Current pharmacotherapies available for the treatment of schizophrenia include typical and atypical antipsychotics but their clinical efficacy is compromised by the slow onset of effect and significant side-effect profile. Cannabidiol is a derivative of the Cannabis sativa plant which has shown antipsychotic potential in several preclinical and clinical studies. This review will highlight the results of these studies and discuss the need for further investigations into the neuropharmacology of Cannabidiol as an antipsychotic.
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms